Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Vesalius Therapeutics

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    GSK shares promising phase 3 results for linerixibat in PBC-related itch

    Pruritus is experienced by up to 90% of patients with the rare liver disease

    - PMLiVE

    GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

    Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

    - PMLiVE

    GSK’s five-in-one meningococcal vaccine recommended by CDC advisory committee

    Penmenvy combines the antigenic components of GSK's approved Bexsero and Menveo vaccines

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

    Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links